Skip to content

Medical emergency? What to do

Experimental vaginal gel inhibits HIV and HSV

3-RXPublished January 25, 20062 min read

Key points

  • Vaginal application of the PRO 2000 gel exerts activity against HIV and herpes simplex virus (HSV), investigators report in The Journal of Infectious Diseases.
  • PRO 2000 gel (Indevus Pharmaceuticals) is a synthetic compound that prevents HIV entry into cells by interacting with the proteins on the surface of the virus.
  • Upon exposure to HIV, there was a significant reduction in HIV levels in cell samples from subjects treated with PRO 2000 compared with cells treated with the placebo.
  • The authors also noted potent anti-HSV activity with PRO 2000 compared with placebo.

Vaginal application of the PRO 2000 gel exerts activity against HIV and herpes simplex virus (HSV), investigators report in The Journal of Infectious Diseases.

However, PRO 2000 and the many other microbicides being investigated to protect against HIV transmission face multiple challenges before they can made widely available, authors of a second Journal article note.

PRO 2000 gel (Indevus Pharmaceuticals) is a synthetic compound that prevents HIV entry into cells by interacting with the proteins on the surface of the virus. While this agent has demonstrated the ability to inhibit HIV and HSV in cell cultures and in animal models, it was not known if it would be active after application in the human vagina.

Dr. Betsy C. Herold, from Mount Sinai School of Medicine in New York, and colleagues recruited 20 HIV-infected women. Cell samples from the vagina and cervix were collected before and one hour after vaginal application of 2 milliliters of the PRO 2000 gel or an inactive placebo gel.

Upon exposure to HIV, there was a significant reduction in HIV levels in cell samples from subjects treated with PRO 2000 compared with cells treated with the placebo.

Herold's group conducted a similar experiment using a virus that had surface proteins cloned from a HIV type that predominates "after sexual transmission and may be more readily transmitted via mucosal routes." HIV infection was inhibited by greater than 99 percent in cervical and vaginal cells exposed to PRO 2000.

The authors also noted potent anti-HSV activity with PRO 2000 compared with placebo.

"This trial demonstrates for the first time that a candidate microbicide is sufficiently bioavailable and retains substantial anti-HIV and anti-HSV activity after intravaginal application," Herold and her team conclude.

In the second paper, Drs. Darpun Dhawan and Kenneth H. Mayer, from Brown Medical School in Providence, Rhode Island, report that more than 30 other microbicides are under investigation, including 15 that are being studied in clinical trials.

Strategies of candidate microbicides include disruption of the HIV membrane, alteration of the vaginal pH, inhibition of HIV receptors.

Major obstacles that remain are developing ways for preclinical testing to evaluate safety and potential microbicidal resistance in the genital tract.

Other challenges include the need to enroll thousands of HIV-uninfected, high-risk subjects in clinical trials that will last for several years and the development of agents to prevent transmission during anal intercourse.

SOURCE: The Journal of Infectious Diseases, January 1, 2006.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underAIDS/HIV

Keep reading

AIDS/HIV

Economic crisis could worsen HIV/AIDS epidemic: UN

Economic crisis and climate change concerns could affect the fight against the AIDS virus and lead to a "universal nightmare", the head of the United Nations' agency for HIV/AIDS said on Sunday. The global economic…

2 min read

AIDS/HIV

Possible cure for HIV patients?

On December 7th, an article was published in PLoS One that explained that researchers from UCLA AIDS Institute have found a way to use human stem cells to fight HIV-infected cells. The human stem cells can be…

1 min read

AIDS/HIV

HIV-infected Chinese children struggle with stigma

The second storey of this nondescript building in Fuyang city in China's central province of Anhui houses HIV-positive orphans, but unlike many other similar establishments, there are no signboards outside. Heavy…

4 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.